Artera has received FDA clearance for ArteraAI Breast, a digital-pathology tool the company says is the first and only FDA-cleared AI system that stratifies risk for patients with early-stage, hormone receptor-positive, HER2-negative invasive breast cancer, according to the company’s announcement in May 2026. The clearance extends Artera’s existing prostate-cancer AI platform into a second tumor type and gives oncologists a new data point when deciding whether a patient needs chemotherapy on top of hormone therapy.
How the test works
ArteraAI Breast runs directly on digitized images of a patient’s own surgical resection tissue combined with standard clinical variables, without requiring any additional biopsy or a separate specimen sent to an outside lab, according to Artera’s clearance announcement. Because it works from slides already generated during routine pathology workflows, the company says results can come back the same day, in contrast to genomic assays that typically require tissue to be shipped out and can take one to two weeks to return a score.
The evidence behind the clearance
Artera’s submission leaned on outcomes data from the NSABP B-20 trial, a National Surgical Adjuvant Breast and Bowel Project study that has long served as a benchmark for chemotherapy-benefit research in HR-positive, HER2-negative breast cancer. According to coverage in CancerNetwork and MedTech Dive, the model demonstrated independent prognostic value — meaning it separated patients into meaningfully different risk groups — and predictive value for chemotherapy benefit, meaning it identified which patients were more likely to benefit from adding chemo to their treatment plan, using a predefined risk-score cutoff to split patients into low- and high-risk categories.
What oncologists are weighing
Breast cancer treatment decisions for HR-positive, HER2-negative disease have for two decades leaned on genomic recurrence-score assays. A same-day, tissue-based AI alternative is attractive to community oncology practices that don’t want to wait on an outside lab, but some clinicians will want to see how ArteraAI Breast’s risk calls line up against those established genomic tests in head-to-head use before changing practice patterns, particularly for patients in the gray zone where a chemotherapy decision is genuinely close. Patient advocates have also pushed, in other AI-pathology rollouts, for clarity on how a risk score is explained to a patient weighing months of chemotherapy against a statistical estimate generated by a model.
Part of a bigger platform bet
Artera built its reputation on a prostate-cancer version of the same underlying approach, which uses multimodal AI to combine pathology images with clinical data to predict long-term outcomes and treatment benefit. Extending into breast cancer signals the company is trying to become a general risk-stratification layer across tumor types rather than a single-cancer specialist, competing for space in oncology workflows against both legacy genomic-assay makers and a wave of newer digital-pathology entrants.
Regulatory backdrop
The clearance arrives as digital pathology has become one of the FDA’s more active oncology AI categories in 2026, alongside tools such as Cercare Medical’s AI-powered brain tumor segmentation module, cleared the following month, and continued expansion of lung-cancer screening AI like Qure.ai’s qXR-LN, which hospital systems such as University Hospitals Cleveland Medical Center have been deploying for chest X-ray-based lung nodule detection. Medical News Today and 360Dx both described ArteraAI Breast as notable precisely because it is a pathology-based test rather than an imaging or genomic one, a category the FDA has cleared relatively few devices in to date.
What’s next
Artera has not published a commercial rollout timeline, but the company’s public statements frame ArteraAI Breast as the leading edge of a broader push into breast oncology. The near-term questions for hospital pathology departments are practical: how the tool integrates with existing digital-slide-scanning infrastructure, what it costs relative to genomic recurrence-score assays, and whether payers will reimburse a same-day AI risk score the way they currently reimburse the genomic tests oncologists have relied on for years. Reimbursement pathways for AI-based pathology tools have historically taken longer to establish than for the imaging-AI category, since payers are still building coverage policies specific to tissue-based algorithmic risk scores, and Artera will likely need additional peer-reviewed validation studies beyond the NSABP B-20 dataset before broad payer coverage follows. For a company that has spent years proving out its approach in prostate cancer, breast cancer represents a much larger addressable patient population — and a much higher bar for clinical acceptance, given how entrenched genomic testing already is in that specific treatment decision.
Photo: cottonbro studio / PEXELS via Pexels
